Slingshot members are tracking this event:

Novartis (NVS) presented new Cosentyx (secukinumab) data from the prospective Phase III SCALP study

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 16, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cosentyx, Phase 3 Study, Scalp, Secukinumab